Heart Transplantation in Adriamycin-Associated Cardiomyopathy: An UNOS Analysis

In a large UNOS (United Network for Organ Sharing) analysis of heart transplant recipients, there was no difference in short-term and long-term survival for patients with end-stage adriamycin-associated cardiomyopathy compared to patients with ischemic or dilated cardiomyopathy.1
Patients with adriamycin-associated cardiomyopathy were younger, more likely women, with higher pulmonary vascular resistance (PVR) but received fewer bridge-to-transplant left ventricular assist devices (LVADs) despite an overall increase in LVAD use during the study period.
There was no difference in death from malignancy up to 5 years post-transplant.